Reducing Cardiovascular Risk and Renal Risk With SGLT2 Inhibitors: Exploring the Evidence

Sunday, September 15, 2019
Symposium: 6:30 PM - 8:00 PM

Pennsylvania Convention Center
Meeting Room 201 A/B
1101 Arch Street
Philadelphia, Pennsylvania

Chair
Mikhail Kosiborod, MD
Professor of Medicine
University of Missouri Kansas City
Kansas City, Missouri

Faculty
George Bakris, MD
Professor of Medicine
University of Chicago School of Medicine
Chicago, Illinois

Robert Mentz, MD
Associate Professor of Medicine
Duke University School of Medicine
Durham, North Carolina

Agenda
6:30 pm  Introduction
Mikhail Kosiborod, MD (Chair)

6:35 pm  Heart Failure with Diabetes: Double Trouble
Robert Mentz, MD

6:55 pm  SGLT2 Inhibitors and Cardiovascular Outcomes
Mikhail Kosiborod, MD

7:15 pm  SGLT2 Inhibitors and Renal Outcomes: Interpreting the Evidence
George Bakris, MD

7:35 pm  Panel Discussion: Using SGLT2 Inhibitors in Practice—Practical Considerations

7:45 pm  Question-and-Answer

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Accredited Sponsor:
Heart Failure Society of America

Program management services provided by

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.